Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conbercept - Chengdu Kanghong Biological Science & Technology

Drug Profile

Conbercept - Chengdu Kanghong Biological Science & Technology

Alternative Names: KH902; Recombinant human VEGF receptor-Fc fusion protein

Latest Information Update: 12 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Kanghong Biological Science & Technology
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Phase III Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 21 Dec 2018 Chengdu Kanghong Biotechnology initiates enrolment in the PANDA-2 phase III trial for Wet age-related macular degeneration in USA (NCT03630952)
  • 25 Sep 2018 Phase-III clinical trials in Wet age-related macular degeneration in USA (Intravitreous) (NCT03577899)
  • 15 Aug 2018 Chengdu Kanghong Biological Science & Technology plans the phase III PANDA-2 trial for Neovascular age-related macular degeneration (In adults, In the elderly) in USA (Intravitreal) (NCT03630952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top